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http://dx.doi.org/10.1016/j.ccell.2015.07.013SUMMARYTumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM)
patients. Thus, insights on the evolutionary process at recurrence are critical for improved patient care.
Here, we describe our genomic analyses of the initial and recurrent tumor specimens from each of 38
GBM patients. A substantial divergence in the landscape of driver alterations was associated with distant
appearance of a recurrent tumor from the initial tumor, suggesting that the genomic profile of the initial tumor
can mislead targeted therapies for the distally recurred tumor. In addition, in contrast to IDH1-mutated
gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treat-
ment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen.INTRODUCTION
Glioblastoma multiforme (GBM; World Health Organization
grade IV glioma) is the most common and most aggressive brain
tumor (Furnari et al., 2007; Tanaka et al., 2013). GBMs can be
classified into two categories, on the basis of the history of tumorSignificance
Although previous sequencing studies examined the genomic
genomic evolution patterns to tumor location or treatment reg
longitudinal pairs reveal that a recurrent tumor at a distant bra
profile compared with the initial tumor, suggesting that the lo
genomic profile of the initial tumor to guide targeted therapie
IDH1-wild-type primaryGBMs have low risk for TMZ-induced h
provide critical insights for informed clinical decisions.
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(primary GBMs), and the remainder progress from low-grade
(grades I–III) gliomas (secondary GBMs). The current therapeu-
tics for GBM serve mostly as palliative measures. Despite
aggressive treatment with surgery, radiation, and the alkylating
agent temozolomide (TMZ), GBM almost always recurs, andlandscape of GBMs and their evolution, they did not relate
imens. Our integrative clinical and genomic analyses of 38
in site from the initial tumor has a highly divergent genomic
cation of recurrence should be considered when using the
s for the recurrent tumor. Our study also demonstrates that
ypermutation following the standard regimen. These findings
c.
the median survival of GBM patients is only 15 months (Stupp
et al., 2005).
Great strides have been made in understanding the genomic
architecture of GBM. The Cancer Genome Atlas (TCGA)
(Brennan et al., 2013; Cancer Genome Atlas Research Network,
2008) and other genomic studies of GBM have identified several
core oncogenic pathways, such as p53, Rb, and receptor
tyrosine kinase (RTK)/Ras/phosphoinositide 3-kinase (PI3K)
signaling (Cancer Genome Atlas Research Network, 2008), as
well as MGMT (Esteller et al., 2000), IDH1 (Parsons et al., 2008;
Yan et al., 2009), TERT (Killela et al., 2013), and chromatin
modifier genes such as H3F3A and ATRX (Jiao et al., 2012;
Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al.,
2012a). Transcriptional profiling has shown that GBMs can be
stratified into four or five molecular subtypes (Noushmehr
et al., 2010; Verhaak et al., 2010). In addition, a genomic study
on longitudinal pairs of GBMs (Kim et al., 2015) described the
patterns of genomic evolution at recurrence. However, because
of the unavailability of the full clinical data, including magnetic
resonance (MR) images and treatment dosages for each patient,
the study provided limited insights into the clinical relevance of
the genomic evolution patterns.
In contrast to other solid tumors, glioma cells do not depend
on intravascular or lymphatic routes to spread (Cuddapah
et al., 2014). Instead, glioma cells migrate mainly through
perivascular space and the brain parenchyma. Accordingly,
although metastasis into extracranial tissues is uncommon,
GBM cells are highly invasive and infiltrative in the brain. Hence,
GBMs recur not only at the sites of the initial tumors (local recur-
rence) but also commonly at different anatomical sites of the
brain (distant recurrence), including in the other hemisphere
relative to the initial tumor site. Although this pattern of tumor
recurrence has been recognized in the clinic, few, if any, studies
have examined the evolutionary processes leading to local
versus distant recurrence.
Another important question about the recurrence of primary
GBMs concerns the type and extent of the genomic damage in-
flicted by TMZ treatment. TMZ is a potent DNA-damaging agent
that alkylates guanine residues (Stevens and Newlands, 1993).
Although mutagenic effects of TMZ are well recognized (Bodell
et al., 2003), its therapeutic benefit in extending GBM patients’
survival has been demonstrated in large cohort studies (Stupp
et al., 2005, 2007). In a recent study by Johnson et al. (2014),
tumor genome evolution from IDH1 mutation-harboring low-
grade gliomas to higher grade malignancies was examined by
sequencing in 23 patients. The authors observed that in 6 of
the 10 TMZ-treated glioma patients, the recurrent tumors dis-
played TMZ-associated hypermutation—a massive accumula-
tion of mutations known to be induced by TMZ treatment
(C-to-T transition in CpC and CpT contexts)—and the same tu-
mors displayed more oncogenic aberrations and progression
to grade IV at recurrence. These findings were taken to imply
that TMZ treatment might have side effects for patients with
low-grade gliomas. Because TMZ is part of the standard of
care for GBM patients, a very important issue is whether TMZ-
associated hypermutation is frequent also in primary GBMs.
Incidents of hypermutation had been reported in GBM tumors
from patients who were previously treated with alkylating agents
including TMZ and CCNU (lomustine) (Cahill et al., 2007; CancerCanGenome Atlas Research Network, 2008; Hunter et al., 2006; Kim
et al., 2015; Yip et al., 2009). However, solid conclusions had not
been drawn, because of the limited number of tumors analyzed
and the lack of sufficient clinical and genomic information, such
as the dose and duration of TMZ treatment and IDH1/2mutation
status. A better understanding of the mutagenic characteristics
of TMZ will help in weighing the beneficial and adverse effects
of TMZ for maximal clinical benefit.
RESULTS
Paired GBM Tumor Specimens from 38 Patients
We obtained paired longitudinal specimens from each of the 38
GBM patients (34 primary and 4 secondary GBM patients; Fig-
ures S1A and S1B and Table S1). Treatment-naive initial tumors
were available for 35 cases; for the other 3 cases (01, 04, and 07;
all 3 were secondary GBM cases), we used the first recurrent tu-
mors in lieu of initial tumors. These first recurrent tumors were
naive to TMZ and radiation treatment, except for case 07, whose
first recurrent tumor was previously treated with radiation (Fig-
ure S1B). All 38 patients received both TMZ and radiation treat-
ment between the surgical procedures during which specimens
were obtained, except for case 07, who was treated only with
TMZ between the procedures. Tumor specimens were sub-
jected to whole-exome sequencing (WES; 27 cases at the me-
dian depth of 74X; WES for the matched normal was done for
22 of the 27 cases at the median depth of 68X), RNA sequencing
(RNA-seq; 30 cases), and array-comparative genomic hybridiza-
tion (aCGH; 16 cases).
Substantial Genomic Divergence at Distant Recurrence
To determine the extent of genomic divergence between the
initial and recurrent tumors, we first identified somatic mutations
in each tumor and compared the mutation profiles between the
initial and recurrent tumors in each case. For this analysis, we
used 22 cases for which WES data were available for both the
tumor and matched normal tissues, as the somatic origins of
mutations can be unambiguously determined for these cases
(Figure S1C). Mutation calling was done using MuTect, a widely
used program (Cibulskis et al., 2013). To validate the mutation
calls, we used two independent approaches. First, we per-
formed Sanger sequencing for a subset of mutations, with
mutant allele fraction (MAF) as low as 0.07 and read depth as
low as 11 (Figure S1D and Table S2). Eighty-five percent
(22 of 26) of tested mutation calls were validated, even though
only a trace amount of genomic DNA was used for some reac-
tions because of the low quantity of available material, and
different specimens of the same tumors had to be used in
some cases because of the unavailability of the original DNA
samples. Second, we systematically compared WES mutation
calls with those from the corresponding RNA-seq data sets.
For this analysis, DNA and RNA were simultaneously prepared
from the same piece of a tumor specimen. When subjecting
WES mutation calls whose locus is expressed (covered by
four or more reads in RNA-seq data), more than 92% of the
WES mutation calls with read depth R 20 and MAF R 0.2
were confirmed in the corresponding RNA-seq data (Fig-
ure S1E). Together, these results support high accuracy of our
WES mutation calls.cer Cell 28, 318–328, September 14, 2015 ª2015 Elsevier Inc. 319
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Figure 1. Substantial Genomic Divergence at Distant Recurrence
(A) Mutation retention ratio and its relationship to the location of recurrence. For the longitudinal sampling panel (initial-recurrent tumor pairs; indicated with light
and dark purple for local and distant recurrence cases, respectively), mutation retention ratio is defined as the percentage of mutations from the first available
tumor retained in the last available recurrent tumor. For the geographic sampling panel (two geographically separated specimens of a common initial tumor;
indicated with green), mutation retention ratio is the average of the two possible ratios. For box plots, the line inside the box is the median; the top and bottom of
the box are the first and third quartiles, respectively; the lines above and below the box represent 1.5 3 interquartile range above and below the median,
respectively; and the dots mark individual data points. For p values, t tests were used. Somatic mutations (MAFR 0.2 and read depthR 20) in the 22 cases with
WES data available for both the tumor and normal tissues were considered. Case labels (shown below the bar plot): I, initial tumor; R, recurrent tumor. MGMT
promoter methylation status: M, methylated; U, unmethylated.
(B) The average fractions of shared and private mutations in the initial and recurrent tumors. Mutations considered for this analysis are as in (A).
See also Figure S1 and Tables S1, S2, S3, and S4.In addition, we conducted ultra-deep sequencing for four tu-
mor specimens to exclude the possibility that the depth of our
WES (74X) was not sufficient for the reliable detection of low-fre-
quency mutations; frequent failures in the detection of low-fre-
quency mutations may lead to misclassification of many shared
mutations into private mutations, overestimating the number of
private mutations. Our results strongly argue against that possi-
bility: among the 17 private mutations tested by ultra-deep
sequencing (minimumdepth, 200X;mean depth, 1,001X), almost
all (94% [16 of 17]) were confirmed to be absent from the tumor in
which the mutations were originally undetected by WES (Fig-
ure S1F). Examination of an additional pair of tumors with the
standard WES and ultra-deep sequencing also confirmed that
all of the 29 mutations called as private by WES were indeed
highly likely to be private (Figure S1G).
Having validated somatic mutations by multiple approaches,
we determined the fraction of initial tumor mutations that were
preserved in the recurrent tumors (mutation retention ratio) in
each pair. Mutation retention ratios of the 22 cases varied widely
from 11% to 97%, with two noticeable clusters near 30% and320 Cancer Cell 28, 318–328, September 14, 2015 ª2015 Elsevier In80% (Figure 1A); this bimodal distribution of mutation retention
levels was also reported in recent studies on paired gliomas
(Johnson et al., 2014) and GBMs (Kim et al., 2015). Because a
low mutation retention ratio is an indicator of branched evolution
and substantial genomic divergence of the recurrent tumor from
the initial tumor, we hypothesized that tumors with low retention
ratios might be associated with specific clinical, biological, or
genomic parameters (e.g., age, sex, radiographic tumor loca-
tion, transcriptome subtype, MGMT promoter methylation,
driver alterations). Statistical analysis showed no significant cor-
relation of the mutation retention ratio with any of these param-
eters after multiple hypotheses correction, except for one: low
mutation retention ratio was significantly correlated with distant
recurrence (p = 0.003, Pearson correlation test, Bonferroni-cor-
rected; Table S3). All 7 distant recurrent tumors retained fewer
than half of the initial tumor mutations (25% on average). In
contrast, 12 of 15 local recurrent tumors showed >50%mutation
retention (70% on average) (Figures 1A and 1B). This difference
was highly significant by all other statistical tests applied (p <
0.002 by t test, Wilcoxon test, and Kolmogorov-Smirnov test),c.
demonstrating that distally recurred tumors were highly diver-
gent from the initial tumors, unlike locally recurred tumors.
Intratumoral heterogeneity has been well recognized in
GBM (Holland, 2000), and recent studies using multi-region
sequencing (Johnson et al., 2014; Sottoriva et al., 2013), fluores-
cence in situ hybridization (Snuderl et al., 2011), and single-cell
sequencing (Francis et al., 2014; Nathanson et al., 2014; Patel
et al., 2014) have collectively provided a more detailed charac-
terization of this heterogeneity. To confirm that the genomic
divergence of distant recurrent tumors observed above was
not due to intratumoral heterogeneity, we collected and profiled
two specimens from each of six new GBM cases (all with the
matched normal) and assessed their degree of genomic diver-
gence. In this ‘‘geographic sampling panel’’ (Table S4), two
distinct specimens were sampled from a common untreated tu-
mor of each patient (i.e., multi-region sequencing). To obtain an
upper bound for intratumoral heterogeneity, we sampled pheno-
typically distinct specimens, with ‘‘phenotype’’ measured by (1)
positive versus negative staining by a tumor-visualizing fluores-
cent dye, 5-aminolevulinic acid (Gliolan) (Sottoriva et al., 2013),
(2) infiltrating edge versus central mass lesions, or (3) lobal
versus ventricle-invading lesions (Figure S1H). In this geographic
sampling panel, mutation retention ratios from the six cases
(83% on average) were higher than the levels in the local recur-
rences (70% on average) and far higher than the levels in the
distant recurrences (25% on average) (p = 0.001, Wilcoxon
test) (Figure 1A). These data suggest that although intratumoral
geographic heterogeneity does exist in GBMs, it cannot account
for the striking genomic divergence in distant recurrence.
Tumor Evolution in the Cases with Three Longitudinal
Specimens
Analysis of multiple longitudinal samples can potentially provide
a more comprehensive view on the spatiotemporal evolution of
GBMs. Although multiple surgical resections after the initial sur-
gery are very rare for primary GBM patients, we were able to
obtain such specimens from four patients. We examined clinical
history and genomic evolution in detail for each of these cases.
For case 02 (Figure 2A), MR images showed that both resected
recurrent tumors (R2 and R3) were at the same anatomical loca-
tion as the initial tumor, which suggested that both the recurrent
tumors likely retained a majority of the initial tumor mutations.
This prediction was confirmed by our genomic analysis, which
showed that the common ancestor clone of both recurrent
tumors retained 76% (115 of 151, indicated by pie charts in
Figure 2A) of the initial tumor mutations. For cases 09 and 18
(Figures 2B and 2C), two resected recurrent tumors were at a
different anatomical location from the initial tumor in each
case, making it likely that only a minor portion of the initial tumor
mutations were retained in the recurrent tumors. Indeed, our
genomic analysis showed that the common ancestor clone of
the two recurrent tumors of each case retained fewer than
half––35% (31 of 88) for case 09 and 33% (45 of 135) for case
18––of the initial tumor mutations. For case 09, we note that
despite the large number of private mutations (125), R3 retained
a majority of R1 mutations (68 of 111 [61%]), indicating that R3
had locally arisen from R1. For case 33 (Figure 2D), the first
recurrent tumor was local and the second recurrent tumor was
distal from the initial tumor. Our genomic analysis confirmedCanthat the first recurrent tumor retained 87% (88 of 101) of the
mutations from the initial tumor, whereas the second recurrent
tumor retained only 45% (45 of 101). Together, these four cases
further illustrate that a distant location of a recurrent tumor is a
strong indicator of a low level of mutation carry-over from the
initial tumor to the recurrent tumor––hence, branched evolution
and substantial divergence of the tumors.
Divergence in Key GBM Driver Gene Alterations
To determine whether the substantial divergence in the overall
mutational profile at distant recurrence entails changes in key
GBM-driving events, we examined our tumor pairs for the alter-
ations (including point mutations, structural variants, and copy
number changes) that are frequently found in the TCGA GBMs
(Brennan et al., 2013; Cancer Genome Atlas Research Network,
2008). Among these, the most prominent alterations in our
cohort were deletions of CDKN2A/B and PTEN, inactivating mu-
tations in TP53 and PTEN, and activating mutations, structural
variants, or amplification of EGFR. These alterations were de-
tected in three or more cases of both local and distant recur-
rence groups (Figures 3A and S2A). We found that these GBM
driver alterations were more frequently present as private events
in distant recurrence cases (13 of 23 [57%]) than in local recur-
rence cases (7 of 35 [20%]) (p = 0.006, Fisher’s exact test). For
instance, TP53 mutations were private in only 1 of 6 local recur-
rence cases, whereas they were private in all 4 distant recur-
rence cases (p = 0.02). PTENmutations showed the similar trend
(private in 0 of 3 and 3 of 4 in local and distant recurrence cases,
respectively). Together, these results suggest that, in compari-
son with the initial tumors, distant recurrence entails more diver-
gence in alterations of core driver genes than local recurrence.
Convergent Evolution of the Paired Tumors
Through our paired analysis, we found evidence for convergent
evolution, that is, independent clonal evolution to acquire
different genomic alterations in the same gene (Figures 3A and
3B). For example, in the initial tumor of case 20, two mutations
of EGFR—variant III (Batra et al., 1995; Sugawa et al., 1990)
and A1148T—were detected at MAFs of 0.49 (73 of 148) and
0.12 (496 of 4,282), respectively. In thematched recurrent tumor,
however, the above mutations were not detected; instead, an
activating EGFRmutation G598V (Lee et al., 2006) was detected
at an MAF of 0.19 (123 of 642). Similarly, while the initial tumor of
case 10 harbored a TP53mutation A161T (MAF = 0.27; 27 of 100)
in its DNA-binding domain, its recurrent tumor contained a
different TP53 mutation in the same domain, A138V (MAF =
0.48; 43 of 90). In addition, in case 18, potentially functional
PTEN,RB1, andNF1mutations in the initial tumor were switched
to different mutations of the same type in all three genes in the
recurrent tumors (Figures 2C and 3B).
Evidence of convergent evolution was also found at the
pathway level. The CDKN2A/B locus encodes INK4 and ARF
proteins, which are central negative regulators of INK4-Rb and
ARF-p53 pathways, respectively. In case 09, the initial tumor
harbored RB1 heterozygous deletion (for INK4-Rb pathway) in
addition to TP53 R158H mutation (MAF = 0.48 [11 of 23]; for
ARF-p53 pathway) (Figures 2B, 3B, 3C, and S2B). These genes
encode components of INK4-Rb and ARF-p53 pathways (Fur-
nari et al., 2007). In contrast, the last recurrent tumor (R3) ofcer Cell 28, 318–328, September 14, 2015 ª2015 Elsevier Inc. 321
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Figure 2. Spatiotemporal Tumor Evolution in Four Patients
(A–D) Treatment histories and tumor phylogenies for case 02 (A), case 09 (B), case 18 (C), and case 33 (D) with three longitudinal tumor specimens: the initial (I) and
two recurrent (R) tumors each. LD-TMZ, low-dose TMZ; RT, radiation therapy; CCRT, concurrent chemoradiotherapy. MR images are preoperative; red arrows
indicate the tumor tissues that were resected. On time lines, pink arrows indicate the times of surgical procedures fromwhich no specimen was collected, hollow
circles indicate the last follow-up, and solid circles indicate patient death. The phylogenetic trees belowMR images illustrate the evolutionary relationship among
the three tumors of each case. For each branch, the number of somatic point mutations and indels (MAFR 0.2 and read depthR 20) and the names of select
mutated cancer genes that are attributed to the branch are shown. The length of a branch is proportional to the number of point mutations. Labeled in red and blue
are focal, high-amplitude amplification (R1.5, log2 scale) and heterozygous/homozygous deletion (%0.5), respectively. Labeled in green are genes with point
mutations or indels. Pie charts next to recurrent tumor labels indicate the fraction of initial tumor mutations that are found in the recurrent tumor.
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Figure 3. Divergence and Convergence of
Key GBM Driver Alterations at Recurrence
(A) Private or shared presence of key GBM driver
gene alterations in local and distance recurrence
cases. Alterations detected in three or more cases
of both local and distant recurrence groups
were examined. The 22 cases with WES data
available for both the tumor and normal tissues
were considered. The following alterations
were considered: point mutations and indels
(MAF R 0.2 and read depth R 20) and copy
number changes (R1.5 and%0.5 for focal, high-
amplitude amplification and heterozygous/homo-
zygous deletion, respectively; log2 scale) detected
in WES; structural variants (SVs; MAF R 0.2 and
read depthR 20) detected in RNA-seq.
(B) Summary of changes in key genes/pathways in
the four cases that show evidence of convergent
evolution.
(C) Private or shared mutations in key GBM driver
pathways. Cases and alterations that are consid-
ered for this analysis are as in (A).
See also Figure S2 and Table S5.this patient did not have the above alterations but instead had
homozygous deletion of CDKN2A. Therefore, both INK4-Rb
and ARF-p53 pathways were dysregulated in both the initial
and recurrent tumors but at different nodes of the pathway in
each tumor. In sum, these results suggest that although the initial
and recurrent tumors frequently branch out early and evolve
independently, in some cases, they experience common selec-
tive pressure to acquire alterations in overlapping driver genes
or pathways.
Distinct Pathway Alteration Landscapes of Initial versus
Recurrent Tumors
Substantial difference in driver alterations between the initial
and recurrent tumors suggests the possibility that recurrent
tumors have a distinct landscape of oncogenic pathway
alterations compared with initial tumors. Large-scale genomicCancer Cell 28, 318–328, Seprofiling studies, including the TCGA
GBM study (Cancer Genome Atlas
Research Network, 2008), identified
deregulation of four major pathways:
RTK-MAPK, RTK-PI3K, INK4-Rb, and
ARF-p53 pathways. Consistent with this,
we found the four pathways to be altered
in a majority of our initial tumors: 68% for
RTK-MAPK, 82% for RTK-PI3K, 73% for
INK4-Rb, and 78% for ARF-p53 (Figures
3C and S2B). In our recurrent tumors,
pathway alterations were detected even
more frequently: 86% for RTK-MAPK,
91% for RTK-PI3K, 77% for INK4-Rb,
and 86% for ARF-p53. In addition, the
number of tumors that have alterations
in all four pathways was increased in
the recurrent tumor set: from 50% (11
of 22) of initial tumors to 73% (16 of 22)
of recurrent tumors. These data areconsistent with the notion that the recurrent tumors typically
have more comprehensive and extensive alterations in major
oncogenic pathways compared with their corresponding initial
tumors.
We also performed unsupervised pathway analysis on the
basis of the gene expression difference between the matched
initial and recurrent tumors. Using gene set enrichment analysis
(Subramanian et al., 2005), we found that gene sets that are
significantly upregulated in recurrent tumors are predominantly
neural and ion channel gene sets (65% and 13%, respectively;
p < 0.001 for both, after multiple hypothesis correction; Figures
S2C and S2D and Table S5). This result is consistent with a
published finding that infiltrating normal astrocytes protect
brain-metastasized melanoma cells from chemotherapy by
sequestering calcium away from the tumor cells through cell-
to-cell gap junctions (Lin et al., 2010), suggesting a hypothesisptember 14, 2015 ª2015 Elsevier Inc. 323
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Figure 4. Minimal TMZ-Induced Mutations
in Primary GBMs
(A) The number of somatic mutations in the pre-
and post-TMZ treatment tumors. For the cases
with three available longitudinal tumors, the first
and the last tumors were considered. Treatments
administered between the first and last available
resections were indicated; numbers in parenthe-
ses indicate TMZ cycles under the low-dose
regimen. Case label and MGMT promoter
methylation status are as in Figure 1.
(B) Frequency of TMZ-associated somatic muta-
tions in pre-TMZ treatment tumors versus post-
TMZ treatment tumors. Tumors considered for this
analysis are as in (A).
See also Figure S3.that normal neuronal cells in the tumor microenvironment
contribute to GBM recurrence.
Minimal TMZ-Induced Mutations in Primary GBMs
To determine the extent of mutations induced by TMZ, we sys-
tematically examined the number and characteristics of somatic
mutations in our paired pre- and post-TMZ treatment GBM
specimens. Consistent with the results of Johnson et al. (2014),
the post-TMZ treatment tumor from an IDH1-R132H secondary
GBM patient (case 07) in our cohort showed a dramatically
increased number of somatic mutations compared with the
matched TMZ-naive tumor (4,858 versus 119; Figure 4A); this
patient was treated only with TMZ between the two surgical pro-
cedures (Figure S1B). The recurrent tumor in this case had mu-
tations in mismatch repair genes (PMS1 andMSH5), as is typical
for tumors with hypermutation (Hunter et al., 2006; Johnson
et al., 2014). By mutation signature analysis (Alexandrov et al.,
2013; Lawrence et al., 2013), we found that TMZ treatment
was responsible for these mutations (Figures 4B and S3A–
S3C). In sharp contrast, none of the 20 IDH1-wild-type primary
GBM patients—all of whom received TMZ treatment (as part of
concurrent chemoradiotherapy [CCRT] or/and adjuvant chemo-
therapy; Figure S1B)—showed any notable increase in the total
or TMZ-associated mutations in the recurrent tumors compared324 Cancer Cell 28, 318–328, September 14, 2015 ª2015 Elsevier Inc.with the initial tumors (Figures 4A and 4B).
Moreover, the signature of the recurrent
tumor mutations was mostly unchanged
from that of the corresponding initial tu-
mors (Figure S3D). When we extended
our hypermutation analysis to five addi-
tional cases in our cohort for which WES
data were available for the tumors but
not for thematched normal tissues (cases
01, 08, 14, 26, and 36), no evidence of hy-
permutation was detected in post-TMZ
treatment tumors of these cases (Fig-
ure S3E). The lack of TMZ-associated
hypermutation in our primary GBM spec-
imens contrasts with the results from
Johnson et al. (2014) and argues against
the possibility of high risk of TMZ-induced
hypermutation in primary GBMs. The dif-ference between IDH1-mutated and IDH1-wild-type tumors can
be potentially explained by multiple factors, including the differ-
ences in treatment regimen and MGMT promoter methylation
(see Discussion; Figure S3F).
DISCUSSION
Tumor evolution is a dynamic process both spatially and tempo-
rally, and it is often accelerated by therapeutic interventions such
as chemotherapy and radiation. Understanding this evolutionary
process would provide clues for guiding effective therapies. By
integrative genomic analysis of the matched initial and recurrent
tumors from patients with primary GBM, we obtained findings
that have immediate clinical and biological implications. First,
we found two paths of tumor evolution leading to GBM recur-
rence. Distally recurred tumors shared only aminority of initial tu-
mor mutations, indicative of branched evolution (also called
divergent evolution). In contrast, most of locally recurred tumors
shared amajority of initial tumormutations, consistent with linear
evolution. At distant recurrence, genetic divergence between the
initial and recurrent tumors entailed changes in key GBM driver
gene/pathway alterations. Recent studies on paired gliomas
(Johnson et al., 2014) and GBMs (Kim et al., 2015) also reported
two types of genome evolution at recurrence, linear and
branched, on the basis of the extent of genetic similarity between
the initial and recurrent tumors. With full radiographic data avail-
able for all our patients, we found that the pattern of genomic
evolution can be predicted by the location of GBM recurrence
with respect to the initial tumor.
Studies of the paired primary andmetastatic tumors (Wu et al.,
2012b; Yachida et al., 2010) and initial-relapsed leukemia (Ding
et al., 2012; Walter et al., 2012) revealed substantial genomic
divergence between the paired specimens, suggesting that
clonal selection might be a major mechanism in metastasis
and relapse. However, it has been unclear whether such clonal
selection happens at GBM recurrence. Our results suggest
that although GBMs recur within the brain, GBM recurrence at
a distant location of the brain involves a high degree of clonal se-
lection and consequent genomic divergence. For the mecha-
nism of clonal selection at distant recurrence, we speculate
that tumor clones that had diffusely invaded into the brain paren-
chyma at the early stage of tumor development may escape its
dormant state and repopulate the recurrent tumor at distal loca-
tions, a hypothesis worthy of further examination.
Although a large number of clinical trials have been conducted
for recurrent GBM patients who no longer tolerate or respond to
the standard treatment, the treatment options considered in
those trials are based on the genomic profiles of their naive tu-
mors. Our finding that genomic profiles, including alterations of
key drivers, of distant recurrent tumors are highly divergent
from those of the initial tumors raises serious concern that the
genomic profile of the initial tumormaymislead subsequent ther-
apies. Our results suggest that re-biopsy and re-profiling may be
essential for more accurate clinical decisions, at least for pa-
tients with distally recurred tumors.
Finally, our results indicated that in contrast to low-grade
gliomas or secondary GBMs, primary GBMs rarely develop
hypermutation following TMZ treatment. This dichotomy can
be potentially explained by multiple factors, including differ-
ences in treatment regimen. Primary GBM patients in our cohort
received CCRT (which includes radiation and 1.5 cycles
[6 weeks] of TMZ), followed by an additional 5.1 cycles of TMZ
on average (median 6 cycles) as adjuvant therapy (counting
4 week-long regular or low-dose TMZ treatments as 1 cycle).
The regimen is in accordance with the standard treatment proto-
col for primary GBM, which is CCRT followed by an additional 6
cycles of adjuvant TMZ (Stupp et al., 2005). In contrast, our sec-
ondary GBM patient (case 07) and the six low-grade glioma
patients of Johnson et al. (2014) whose tumors developed hyper-
mutation did not receive CCRT but received far more cycles
(17 cycles for case 07 and 11.7 cycles on average for Johnson’s
six patients) of TMZ than did the primary GBM cohort. The higher
total dose of TMZ and the fact that TMZ was administered
outright without the preceding CCRT might have contributed
to the higher incidence rate of hypermutation in the low-grade
gliomas or secondary GBMs with IDH1 mutation.
Another factor that may explain the difference in frequency of
hypermutation is that IDH1-mutated tumors are predisposed to
hypermutation by the followingmechanism. The gain-of-function
IDH1 mutation at arginine 132 causes CpG island methylator
phenotype, and as a result, the IDH1-mutated tumors show
hypermethylation in a large fraction of the genome (Noushmehr
et al., 2010; Turcan et al., 2012), frequently including the pro-Canmoter region of MGMT. The MGMT methylation and conse-
quent MGMT silencing impairs a mechanism for repairing
TMZ-induced DNA alkylation and mutagenesis (Liu and Gerson,
2006). Therefore, the IDH1-mutated tumors have a higher
chance of acquiring inactivating mutations in mismatch repair
genes and resulting hypermutation. Together, we hypothesize
that genetic predisposition, in combination with the larger num-
ber of TMZ cycles administered to patients with IDH1-mutated
tumors, accounts for the higher incidence rate of hypermutation
in these tumors.
Irrespective of potential molecular mechanisms, our results
provide important insights for clinical practice regarding GBM
patients. TMZ-induced hypermutation and resulting large muta-
tional diversity can contribute to drug resistance (Bozic et al.,
2013); our data suggest that such an adverse effect of TMZ is
minimal for IDH1-wild-type primary GBM patients when used
in accordance with the standard regimen. On the other hand,
for patients with IDH1-mutated tumors, who often show MGMT
promoter methylation, TMZ has been considered a preferred
treatment option and is often administered with more cycles
than for other patients; this was based on the proven efficacy
of TMZ for MGMT-methylated tumors (Hegi et al., 2005). How-
ever, on the basis of our study and the prior study on paired
gliomas with IDH1mutations (Johnson et al., 2014), the benefits
of TMZ should now be considered more carefully against its
potentially adverse effects of hypermutation.
In summary, our systematic comparison of the genomic land-
scape of primary GBMs at initial diagnosis and recurrence pro-
vides one explanation for the ineffectiveness of targeted therapy
for distally recurred tumors and illustrates the importance of re-
biopsy and re-profiling for these tumors. Future studies with se-
rial sampling of large cohorts will be needed to characterize
genomic divergence of recurrent tumors in different tumor types
and to measure potential side effects of existing therapies at the
genomic level.EXPERIMENTAL PROCEDURES
Patients and Specimens
This study was approved by the institutional review board at SamsungMedical
Center and Seoul National University Hospital. Surgical specimens and clinical
information were obtained from GBM patients who underwent brain tumor
removal surgery at Samsung Medical Center and Seoul National University
Hospital. Informed consent was obtained from all patients. All patients had
well-annotated clinical information. On the basis of examination of preopera-
tiveMR images, the locations of recurrent tumors relative to initial tumors (local
versus distant) were determined for all recurrent tumors. The presence of non-
necrotic tumor regions in the specimens was confirmed through microscopic
examination by trained pathologists. Histologic diagnoses of tumors were
made by the pathologists. For genomic analysis, parts of the specimens
were snap-frozen and preserved in liquid nitrogen until use. Genomic DNA
and mRNA were extracted using the DNeasy kit and the RNeasy kit (Qiagen),
respectively.WES, RNA-seq, and/or aCGH data were obtained for longitudinal
specimens of 38 cases (i.e., longitudinal sampling panel). The study was de-
signed to characterize how major GBM driver variants change in response
to standard treatments rather than to discover rare variants. As such, the sam-
ple size of 38 cases (pairs or trios of tumors) provided >95%confidence for de-
tecting (1) at least one case of any 10% frequency event (1 among 10 patients
carries the variant) and (2) at least three cases of any 20% frequency event.
The 38 cases were selection biased toward longer survival (median overall sur-
vival 27 versus 15 months in historical cohorts) and younger age (median age
47 versus 56 years in historical cohorts), because those patients aremore likelycer Cell 28, 318–328, September 14, 2015 ª2015 Elsevier Inc. 325
to have undergone more than one surgical procedure. In addition to the longi-
tudinal sampling panel, we obtainedWES data for 6 GBM cases, for which two
geographically distinct specimens were obtained from a common untreated
tumor (i.e., geographic sampling panel). We also used the TCGA data set;
the analysis procedure for this data set is described in Supplemental Experi-
mental Procedures.
aCGH
aCGH was conducted using Agilent SurePrint G3 Human CGH 4 3 180k
arrays, according to the manufacturer’s instructions. aCGH feature
extraction files were processed and normalized using Agilent Genomic
WorkBench 7.0.4.0 with the 022060_20101001.xml design file (obtained
from AgilentCytoGenomics 2.7.11.0). The R package DNAcopy (version
1.30.0) was used to estimate DNA copy number for genomic segments. From
the copy numbers at the segment level, the copy number for each gene was
calculated by averaging the copy numbers of all exonic segments of the gene.
WES
Raw Data
Either the Illumina TruSeq Exome-capture kit (for case 30) or the Agilent
SureSelect kit (for all the other cases) was used for capturing exonic DNA frag-
ments. For sequencing, Illumina HiSeq2000 was used to generate 23 101 bp
paired-end reads.
Somatic Mutation
The sequenced reads in FASTQ files were mapped on the human genome as-
sembly (hg19) using Burrows-Wheeler Aligner version 0.6.2 (Liu et al., 2009).
The initial alignment BAM files were subjected to conventional preprocessing
before mutation calling: sorting, removing duplicated reads, locally realigning
reads around potential small indels, and recalibrating base quality scores
using SAMtools, Picard version 1.73 and Genome Analysis ToolKit (GATK)
version 2.5.2 (DePristo et al., 2011). dbSNP (build ID 135) was used in the
realignment and recalibration processes. Formutation calling,MuTect (version
1.1.4) (Cibulskis et al., 2013) and SomaticIndelDetector (GATK version 2.2)
(Banerji et al., 2012) were used to make high-confidence predictions on so-
matic mutations from the tumor and normal tissue pair. Variant Effect Predictor
(VEP) version 73 (McLaren et al., 2010) was used to annotate the predicted
somatic mutations with potential functional consequences and other relevant
information. Procedures for coverage calculation, mutation calling for tumors
without the available matched normal, mutation validation, and hypermutation
status determination are described in Supplemental Experimental Procedures.
Phylogeny
The evolutionary relationship between multiple tumors obtained from the
same individual was inferred from the patterns of somatic mutations. We used
Phylip version 3.695 to build phylogenetic trees. Only the mutations with read
depthR 5 in all related tumors of each case were used for this analysis.
Copy Number
We used the ngCGH python package version 0.4.4, which generates aCGH-
like data from WES data. The patient-matched normal WES data were used
as the reference for calculating fold changes in copy number in tumors. In
cases in which patient-matched normal data were not available, we created
a ‘‘pseudo-normal’’ profile to be used as the reference. The pseudo-normal
profile is based on averaging a pool of 20 randomly chosen normal WES
data, which were generated using the same sequencing platform and
analysis pipeline as the tumor data. Downstream analyses, including seg-
mentation and calculation of the copy number for each gene, were conduct-
ed as were done for aCGH data. For the tumors for which tumor purity was
calculated, copy numbers were corrected for tumor purity as described in
Supplemental Experimental Procedures. For cases with both aCGH and
WES data, the copy numbers measured from WES data were used for
analysis.
RNA-seq
For all samples, RNA-seq libraries were prepared using the Illumina TruSeq
RNA Sample Prep kit. RNA-seq data were analyzed for three types of informa-
tion: mRNA level, exon skipping, and point mutation. For analysis of mRNA
level, sequenced reads in FASTQ files were trimmed to include only 30 nucle-
otides from the 50 end of each read. The trimmed reads were mapped on hg19
using GSNAP version 2012-12-20 (Wu and Nacu, 2010), not allowing any326 Cancer Cell 28, 318–328, September 14, 2015 ª2015 Elsevier Inmismatch, indels, or splicing. The resulting alignment SAM files were sorted
and summarized into BED files using SAMtools and bedTools (bamToBed
version 2.16.2) (Quinlan and Hall, 2010). The BED files were used to calculate
reads per kilobase of transcript per million reads mapped values for each gene
by using the R package DEGseq (Wang et al., 2010) and the RefSeq gene an-
notations (refFlat table, downloaded from the University of California, Santa
Cruz [UCSC] Genome Browser, last accessed on August 6, 2012). Procedures
for unsupervised pathway analysis and subtype prediction (both analyses are
based on mRNA level data) are described in Supplemental Experimental Pro-
cedures. For analysis of exon skipping, the untrimmed reads in FASTQ files
were aligned on hg19 using GSNAP in the single-end mapping mode, while
allowing splicing. The GSNAP results were parsed to isolate the ‘‘split’’ reads
that span non-canonical splicing junctions (not annotated in the RefSeq or
UCSC Known Gene database), with the minimal anchor of five nucleotides
on each exon. If there weremore than two such split reads between two exons,
the event was called as a skipped exon event between the two exons. For anal-
ysis of point mutations, full-length sequencing reads in FASTQ files were
aligned on hg19 using GSNAP with the same configurations as for skipped
exon detection (single-end mapping mode allowing splicing), except for the
output format: skipped exon analysis used a GSNAP output, while point muta-
tion analysis used a SAM-formatted output. The SAM files were subjected to
the same preprocessing procedures as the ones applied to the WES data,
except that local realignments were restricted to exonic regions, so as not to
confuse normal splicing events as misaligned indels. We identified potential
point mutations using UnifiedGenotyper of GATK and selected mutations
that met the following criteria: (1) per-base sequencing depthR 4, (2) mutant
allele read count R 2, (3) MAF R 0.01, and (4) chromosomal coordinate of
a mutation is registered as ‘‘confirmed somatic mutation’’ in the COSMIC
database. The selected mutation candidates were annotated using VEP as
with WES data.
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